{
  "id": "common-rule",
  "title": "Common Rule",
  "lang": "en",
  "source_lang": "en",
  "summary": "The Common Rule is a shared framework of United States federal regulations governing the protection of people who participate in research.",
  "category": "society",
  "subcategory": "law",
  "type": "work",
  "aliases": [
    "Federal Policy for the Protection of Human Subjects"
  ],
  "generated_at": "2026-11-04",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/common-rule/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/common-rule/",
      "json": "https://aiwiki.page/zh/common-rule.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "The Common Rule, formally known as the Federal Policy for the Protection of Human Subjects, is a set of regulations adopted by multiple agencies of the United States federal government to protect people who participate in research. It establishes requirements for institutional oversight, informed consent, and review by an institutional review board (IRB). The rule applies principally to human-subjects research conducted or supported by participating federal departments and agencies, although institutions may extend comparable requirements to other research. It is not a universal law governing every study involving people."
    },
    {
      "heading": "Legal structure and scope",
      "text": "The Common Rule is a shared regulatory framework rather than a single statute. Participating federal departments and agencies incorporate substantially equivalent provisions into their own regulations. Within the Department of Health and Human Services (HHS), it appears in 45 CFR part 46, subpart A.\n\nThe wider HHS regulations contain additional subparts addressing research involving pregnant women, human fetuses and neonates; prisoners; and children. These additional protections are not themselves part of the Common Rule, although they may apply alongside it. Another HHS subpart addresses IRB registration.\n\nCoverage depends on several questions: whether an activity is research, whether it involves human subjects as defined by the regulations, whether a participating agency conducts or supports it or otherwise makes the regulations applicable, and whether an exemption applies. Institutional policies, funding conditions, and other legal requirements may impose additional obligations.\n\nResearch and human subjects\n\nThe rule generally defines research as a systematic investigation, including research development, testing, and evaluation, designed to develop or contribute to generalizable knowledge. Publication plans alone do not determine whether an activity meets this definition.\n\nA human subject is a living individual about whom an investigator conducting research:\n\n- Obtains information or biospecimens through intervention or interaction, and uses, studies, or analyzes them; or\n- Obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens.\n\nIntervention includes physical procedures and manipulations of a person or their environment performed for research purposes. Interaction includes communication or interpersonal contact. Identifiability generally concerns whether an investigator can readily ascertain a person's identity or associate it with the information or specimen.\n\nThese definitions make the rule relevant to much more than medical experimentation. Interviews, educational studies, behavioral experiments, and research using identifiable records can also fall within its scope. Conversely, some research using information that investigators cannot readily link to individuals may fall outside the regulatory definition of human-subjects research.\n\nThe revised rule expressly excludes certain activities from its definition of research. Examples include specified scholarly and journalistic activities focused directly on particular individuals and certain authorized public health surveillance activities. These exclusions have defined boundaries; they are not blanket exclusions for all journalistic work or all public health investigations."
    },
    {
      "heading": "Historical development",
      "text": "The Common Rule developed from federal efforts to establish enforceable protections for research participants. The National Research Act of 1974 created a national commission to examine the ethical foundations of human-subjects research and strengthened the statutory basis for institutional review.\n\nThe commission's Belmont Report, published in 1979, articulated three principles that remain central to United States research ethics:\n\n- Respect for persons: recognizing individual autonomy and protecting people with diminished autonomy.\n- Beneficence: avoiding harm and seeking a favorable relationship between potential benefits and risks.\n- Justice: distributing the burdens and benefits of research fairly.\n\nThe Belmont Report is an ethical framework, not the Common Rule itself. Its principles helped shape the interpretation and administration of research protections.\n\nIn 1991, multiple federal departments and agencies adopted a common set of human-subjects regulations, giving rise to the name “Common Rule.” A major revision was published in 2017. Following implementation delays, its general compliance date was January 21, 2019. These revised provisions are commonly called the 2018 Requirements, while the older framework is called the pre-2018 Requirements.\n\nResearch initiated before the revised framework's general compliance date can remain subject to the older requirements unless transitioned under the applicable rules. Consequently, both frameworks remain relevant to regulatory administration."
    },
    {
      "heading": "Institutional review",
      "text": "An IRB is a formally constituted committee authorized to review human-subjects research and to approve it, require modifications, or disapprove it. Its function is distinct from scientific peer review, although the scientific design of a study matters when assessing whether exposing participants to risk is justified.\n\nUnder the Common Rule, an IRB must have at least five members with varied backgrounds. Its membership must include scientific and nonscientific perspectives and at least one member unaffiliated with the institution. Members with conflicting interests generally cannot participate in the review of the affected research, except to provide information requested by the board.\n\nFor approval, the IRB must determine, among other things, that:\n\n- Risks to subjects are minimized through sound research design and appropriate procedures.\n- Risks are reasonable in relation to anticipated benefits, if any, and the importance of the knowledge expected.\n- Selection of subjects is equitable.\n- Informed consent will be sought and appropriately documented, unless an authorized exception applies.\n- Monitoring, privacy, and confidentiality protections are adequate where appropriate.\n- Additional safeguards address circumstances in which participants may be vulnerable to coercion or undue influence.\n\nThe regulations define minimal risk by reference to the probability and magnitude of harm or discomfort ordinarily encountered in daily life or during routine physical or psychological examinations or tests. Minimal risk is not the same as an absence of risk.\n\nExpedited review and continuing review\n\nCertain research involving no more than minimal risk and falling within specified categories may receive expedited review by an IRB chair or designated experienced reviewers. “Expedited” describes a regulatory review procedure, not a guaranteed processing time or an exemption from ethical scrutiny.\n\nThe revised Common Rule removed the routine continuing-review requirement for some research, including much research eligible for expedited review, unless the IRB determines otherwise. Other institutional obligations, including reporting relevant problems and obtaining approval for covered changes, may remain."
    },
    {
      "heading": "Informed consent",
      "text": "Informed consent is a process of providing relevant information and enabling a voluntary decision, not merely obtaining a signature. The Common Rule requires information to be presented in understandable language and under circumstances that minimize coercion or undue influence.\n\nOrdinarily, participants must receive information about the study's purpose, procedures, foreseeable risks, expected benefits, confidentiality protections, contacts for questions, and the voluntary nature of participation. Additional disclosures apply when relevant.\n\nThe revised rule requires consent to begin with a concise and focused presentation of the key information most likely to help a prospective participant understand why someone might or might not want to participate. The overall presentation must facilitate understanding rather than merely assemble isolated facts.\n\nFor research involving identifiable private information or identifiable biospecimens, consent generally must explain whether information or specimens might, after identifiers are removed, be used or distributed for future research without additional consent.\n\nAn IRB may approve a waiver or alteration of consent only when applicable regulatory criteria are met. For a general waiver, these include minimal risk, protection of subjects' rights and welfare, and a finding that the research could not practicably be carried out without the waiver. Additional conditions apply to the use of identifiable information or biospecimens. Waiving the requirement to obtain consent is distinct from waiving the requirement for a signed consent document."
    },
    {
      "heading": "Exempt research and broad consent",
      "text": "The revised Common Rule contains eight categories of exempt research. They include specified educational research, certain tests and surveys, some benign behavioral interventions involving adults, and particular forms of secondary research.\n\nAn exemption means that research is exempt from specified Common Rule requirements; it does not mean that every ethical, institutional, or legal obligation disappears. Some exemption categories require limited IRB review, particularly to assess privacy and confidentiality safeguards. Eligibility may also depend on participants' ages, the information collected, and the consequences of disclosure.\n\nThe revised rule introduced broad consent as an optional pathway for the storage, maintenance, and secondary research use of identifiable private information or identifiable biospecimens. Broad consent must meet specified disclosure requirements and is not unrestricted permission for every future use.\n\nInstitutions are not required to adopt broad consent. Other lawful pathways may include study-specific consent, an IRB-approved waiver, an applicable exemption, or research using materials that do not meet the definition of identifiable human-subjects information. If a person is asked for broad consent and refuses, the regulations restrict an IRB's ability to waive consent for the relevant storage, maintenance, or secondary use."
    },
    {
      "heading": "Cooperative research",
      "text": "For covered cooperative research involving multiple United States institutions, the revised Common Rule generally requires reliance on a single IRB for the portion conducted in the United States, subject to specified exceptions. The compliance date for this requirement was January 20, 2020.\n\nThe single-IRB requirement seeks to reduce duplicative review while retaining participant protections. Reliance on one reviewing IRB does not eliminate participating institutions' responsibilities for conducting research appropriately, supplying relevant local information, and fulfilling agreed oversight duties."
    },
    {
      "heading": "Relationship to other protections",
      "text": "The Common Rule operates alongside other regulatory systems.\n\nThe Food and Drug Administration maintains separate human-subject protection and IRB regulations for research within its jurisdiction. A study may be subject to both frameworks, but their coverage and requirements are not identical.\n\nThe HIPAA Privacy Rule governs certain uses and disclosures of protected health information by covered entities and their business associates. HIPAA authorization is legally distinct from research informed consent, even when both are documented together. Compliance with one framework does not automatically satisfy the other.\n\nOther data privacy requirements, state laws, professional duties, and contractual commitments may also apply. A study outside the Common Rule can therefore still carry substantial confidentiality and ethical obligations."
    },
    {
      "heading": "Limits and continuing issues",
      "text": "The Common Rule's reach is tied to regulatory definitions and agency coverage. Privately supported research may fall outside its direct scope unless another applicable requirement or institutional policy brings it within a comparable oversight system.\n\nIts emphasis on identifiable information also creates challenges for research using large datasets. Information that does not meet the rule's identifiability threshold can still raise concerns about reidentification, sensitive inferences, or harms to communities. Such concerns are not resolved solely by determining whether a project legally qualifies as human-subjects research.\n\nResearch governance also involves balancing standardized review with local context, coordinating responsibilities in multisite studies, and assessing consent practices in digital environments. IRB approval establishes that applicable review criteria have been met; it does not guarantee that a study is risk-free, scientifically conclusive, or free from every ethical concern."
    }
  ],
  "links": [
    "united-states",
    "informed-consent",
    "institutional-review-board",
    "law",
    "medicine",
    "public-health",
    "journalism",
    "belmont-report",
    "ethics",
    "peer-review",
    "hipaa-privacy-rule",
    "data-privacy"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}